๐๏ธ Verified NIH Record โข Updated 2025-07-09
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent (NCT05111509)
A Phase 0 First-in-human Clinical Trial of [203Pb]VMT-ฮฑ-NET SPECT/CT for Somatostatin Receptor Imaging of Neuroendocrine Tumors
๐ต Active, Not Recruiting Early Phase1 ๐ Investigational Drug / Biologic Sponsor: Yusuf Menda
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a first in man study to determine if \[203Pb\]VMT-ฮฑ-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.
Who can join: Review the eligibility criteria below.
Location: The University of Iowa โ Iowa City, Iowa
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- The University of Iowa โ Iowa City, Iowa
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuroendocrine Tumor Grade 2
- CapTemY90 for Grade 2/3 NET Liver Metastases โ La Jolla, California
Explore by condition: All Neuroendocrine Tumor Grade 2 clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.